CABA
NASDAQ · Biotechnology
Cabaletta Bio Inc
$3.25
+0.26 (+8.70%)
Open$3.11
Previous Close$2.99
Day High$3.28
Day Low$3.08
52W High$4.23
52W Low$1.26
Volume—
Avg Volume8.23M
Market Cap520.14M
P/E Ratio—
EPS$-1.96
SectorBiotechnology
Analyst Ratings
Strong Buy
16 analysts
Price Target
+1,124.3% upside
Current
$3.25
$3.25
Target
$39.79
$39.79
$29.42
$39.79 avg
$58.63
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 65.93M | 59.67M | 56.91M |
| Net Income | 10.90M | 11.06M | 10.11M |
| Profit Margin | 16.5% | 18.5% | 17.8% |
| EBITDA | 19.62M | 16.47M | 16.10M |
| Free Cash Flow | 6.94M | 6.70M | 7.67M |
| Rev Growth | +19.8% | +7.9% | +20.9% |
| Debt/Equity | 0.22 | 0.21 | 0.21 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $261.07 | +3.99% | 126.9 | 461.26B |
| AMGN | Amgen Inc | $374.15 | +3.55% | 25.9 | 201.93B |
| GILD | Gilead Sciences Inc | $131.27 | +4.21% | 17.7 | 162.98B |
| VRTX | Vertex Pharmaceuticals Inc | $528.04 | +6.03% | 30.4 | 131.79B |
| REGN | Regeneron Pharmaceuticals | $654.27 | +4.73% | 15.5 | 68.59B |
| ALNY | Alnylam Pharmaceuticals Inc | $312.78 | +3.68% | 72.4 | 41.76B |